Therapeutic Asset Ratings

184 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Epirubicin Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma	Northwestern University	P2	B (60)
Hydroxychloroquine Advanced Ovarian Carcinoma	Northwestern University	P2	B (60)
Nivolumab Richter Syndrome	Northwestern University	P2	B (60)
Pembrolizumab Breast Inflammatory Carcinoma	Northwestern University	P2	B (60)
Pembrolizumab Nodal Peripheral T-Cell Lymphoma With TFH Phenotype	Northwestern University	P2	B (60)
Pembrolizumab Recurrent Enteropathy-Associated T-Cell Lymphoma	Northwestern University	P2	B (60)
Pembrolizumab Recurrent Hepatosplenic T-Cell Lymphoma	Northwestern University	P2	B (60)
Pembrolizumab Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma	Northwestern University	P2	B (60)
WP 1066 MGMT-Unmethylated Glioblastoma	Northwestern University	P2	B (60)
VINCRISTINE SULFATE EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	Northwestern University	P2/3	B (60)
Tizanidine Stroke	Northwestern University	P3	B (59)
Encorafenib Stage IV Colorectal Cancer Positive for BRAF V600E Mutation	Northwestern University	P2	B (58)
Hydroxychloroquine Advanced Pancreatic Carcinoma	Northwestern University	P2	B (58)
Hydroxychloroquine Metastatic Pancreatic Carcinoma	Northwestern University	P2	B (58)
Hydroxychloroquine Advanced Malignant Solid Neoplasm	Northwestern University	P2	B (57)
Valproic Acid Moderate Traumatic Brain Injury (TBI)	Northwestern University	P2/3	B (57)
Nintedanib Acute Myeloid Leukemia	Northwestern University	P2	CCC (55)
Fresh Frozen Plasma Moderate to Severe Traumatic Brain Injury	Northwestern University	P2/3	CCC (54)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Posttraumatic Headache	Northwestern University	P2	CCC (53)
Abiraterone Acetate Abnormal DNA Repair	Northwestern University	P2	CCC (53)
Balstilimab Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype	Northwestern University	P2	CCC (53)
Balstilimab Glioblastoma Multiforme	Northwestern University	P2	CCC (53)
Balstilimab Gliosarcoma	Northwestern University	P2	CCC (53)
Balstilimab Newly Diagnosed Glioblastoma	Northwestern University	P2	CCC (53)
Botensilimab Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype	Northwestern University	P2	CCC (53)

Showing 51 to 75 of 184 assets

PreviousPage 3 of 8Next